Biotia

Executive Summary

Biotia is a New York-based health technology company combining next-generation sequencing (NGS) and artificial intelligence (AI) to combat infectious diseases. Founded in 2015, the company develops advanced diagnostic assays and a global pandemic early warning system, aiming to improve pathogen detection, outbreak prediction, and patient care. By leveraging NGS and AI, Biotia seeks to provide rapid, accurate identification of pathogens, enabling proactive responses to emerging threats. The company operates at the intersection of AI, diagnostics, and genomics, positioning itself to address unmet needs in infectious disease management. With a focus on both clinical diagnostics and public health surveillance, Biotia's platform could play a critical role in future pandemic preparedness. The company is private and has not disclosed funding or valuation, suggesting it may be in early commercialization or development stages. Its technology has potential applications in hospitals, reference labs, and global health organizations.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance for NGS-based Infectious Disease Assay50% success
• Q2 2026Strategic Partnership with Public Health Agency65% success
• Q3 2026Series A Funding Round Announcement55% success